Advertisement

Annexins in cardiac tissue: cellular localization and effect on phospholipase activity

Chapter
  • 73 Downloads
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 8)

Abstract

Stimulation of cardiac phospholipid metabolism has diverse biological effects, ranging from subtle changes in cellular function to severe cellular damage. Accordingly, knowledge of the factors governing the activity of cardiac phospholipases is of great biological importance. A possible role of annexins, intracellular proteins that bind to membranes in a calcium dependent manner, as modulators of phospholipase activity has been proposed. In this study we investigated the cell type specific distribution of Annexin V and VIII in the heart. Recombinant Annexin V was used to examine the effect of this type of Annexin on cardiac phospholipase activity. Western blot analysis shows that annexin V is abundantly present in the heart. Using isolated myocytes and cultured cardiac endothelial and fibroblast-like cells, it is demonstrated that the localization of Annexin V is confined to non-myocytes. No positive bands matching the Mw of recombinant Annexin VIII are found in any of the cell types examined. In vitro studies demonstrate that recombinant Annexin V potently inhibits the activity of cardiac membrane-bound phospholipases, acting on their natural surrounding substrate, in a calcium dependent manner. Interestingly, annexin V also inhibits triacylglycerol hydrolysis. In conclusion, the expression of annexins is cell-type specific and suggests a cell-type specific function of these proteins in the heart. The absence of Annexin V in cardiac myocytes dismisses involvement of this annexin in cardiomyocyte phospholipid metabolism. The presence of Annexin V in cardiac endothelial and fibroblasts suggests a regulating role in the phospholipid homeostasis of non-myocyte cell types in the heart. (Mol Cell Biochem 116: 95–101, 1992)

Key words

cardiac annexins cellular damage intracellular proteins endothelial cells fibroblast 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Corr PB, Gross RW, Sobe l BE: Amphipathic met abolites and membrane dysfunction in ischemic myocardium. Circ Res 55: 135–154, 1984PubMedCrossRefGoogle Scholar
  2. 2.
    Van der Vusse GJ., Van Bilsen M, Sonderkamp T, Reneman RS: Hydrolysis of phospholipids and cellular integrity. In Piper HM (ed): Pathophysiology of severe ischemic myocardial injury, Dordrecht, Kluwer Acad Publ, pp 167–193, 1990Google Scholar
  3. 3.
    Dennis EA: Regulation of eicosanoid production: role of phospholipases and inhibitors. Bio/technology 5: 1294–1300, 1987CrossRefGoogle Scholar
  4. 4.
    Hatch HM, O K, Choy PC: Regulation of phosphatidylcholine metabolism in mammalian hearts. Biochem Cell Biol 67: 67–77, 1989PubMedCrossRefGoogle Scholar
  5. 5.
    Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Chow EP, Browning JL, Ramachandran KL, Pepinsky RB: Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320: 77–81, 1986PubMedCrossRefGoogle Scholar
  6. 6.
    Klee CB: Ca2+-dependent phospholipid-(and membrane-) binding proteins. Biochemistry 27: 6645–6653, 1988PubMedCrossRefGoogle Scholar
  7. 7.
    Kaetzel MA, Hazarika P, Dedman JR: Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid binding proteins. J Biol Chem 364: 14463–14470, 1989Google Scholar
  8. 8.
    Pula G, Bianchi R, Ceccarelli P, Giambanco I, Donato R: Characterization of mammalian heart annexins with special reference to CaBP 33 (annexin V). FEBS Lett 277: 53–58, 1990PubMedCrossRefGoogle Scholar
  9. 9.
    Reutelingsperger CPM, Hornstra G, Hemker HC: Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 151: 625–629, 1985PubMedCrossRefGoogle Scholar
  10. 10.
    Hauptmann R, Maurer-Fogy I, Krystek E, Bodo G, Andre H, Reutelingsperger CPM: Vascular anticoagulant beta (VAC-beeta: a novel human Ca+ +/phospholipid binding protein that inhibits coagulation and phospholipase A2 activity. Eur J Biochem 185: 63–71, 1989PubMedCrossRefGoogle Scholar
  11. 11.
    Maurer-Fogy I, Reutelingsperger CPM, Pieters J, Bodo G, Stratowa C, Hauptmann R: Cloning and expression fo cDNA for human vascular anticoagulant, a Ca2+-dependent phospholipid-binding protein. Eur J Biochem 174: 585–592, 1988PubMedCrossRefGoogle Scholar
  12. 12.
    Van Bilsen M, Reutelingsperger CPM, Van der Vusse GJ: Are annexins involved in cardiac phospholipid metabolism? J Mol Cell Cardiol 23 (suppl V): S.51, 1991Google Scholar
  13. 13.
    Linssen MCJG, Vork MM, de Jong YF, Glatz JFC, Van der Vusse GJ: Fatty acid oxidation capacity and fatty acid-binding protein content of different cell types isolated from rat heart. Mol Cell Biochem 98: 19–25, 1990PubMedCrossRefGoogle Scholar
  14. 14.
    Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheats: Procedure and some applications. Proc Natl Acad Sci USA 76: 4350–4354, 1979PubMedCrossRefGoogle Scholar
  15. 15.
    Van der Vusse GJ, Roemen THM, Prinzen FW, Coumans WA, Reneman RS: Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. Circ Res 50: 538–546, 1982PubMedCrossRefGoogle Scholar
  16. 16.
    Roemen THM, Keizer H, Van der Vusse GJ: Quantitative assessment of gamma-linolenic acid in human blood and plasma with capillary gas chromatography. J Chromatogr (Biomed Appl) 528: 447–452, 1990CrossRefGoogle Scholar
  17. 17.
    Van Bilsen M, Van der Vusse GJ, Willemsen PHM, Coumans WA, Roemen THM, Reneman RS: Lipid alterations in isolated, working hearts during ischemia and reperfusion: Its relation to myocardial damage. Circ Res 64: 304–314, 1989PubMedCrossRefGoogle Scholar
  18. 18.
    Davidson FF, Dennis EA, Powell M, Genney JR: Inhibition of phospholipase A2 by ‘lipocortins’ and calpactins: an effect of binding to substrate phospholipids. J Biol Chem 262: 1698–1705, 1987PubMedGoogle Scholar
  19. 19.
    Aarsman AJ, Mynbeek G, Van den Bosch H, Rothhut B, Prieur B, Cornera C, Jordan L, Russo-Marie F: Lipocortin inhibition of extracellular and intracellular phospholipase A2 is substrate concentration dependent. FEBS Lett 219: 176–180, 1987PubMedCrossRefGoogle Scholar
  20. 20.
    Fauvel J, Vicendo P, Roques V, Ragab-Thomas J, Gamier C, Vilgrain I, Chambaz E, Rochat H, Chap H, Douste-Blazy L: Isolation of two 67 kDa calcium-binding proteins from pig lung differing in affinity for phospholipids and in anti-phospholipase A2 activity. FEBS Lett 221: 397–402, 1987PubMedCrossRefGoogle Scholar
  21. 21.
    Cirino G, Flower RJ, Browning JL, Sinclair LK, Pepinski RB: Recombinant human lipocortin 1 inhibits thromboxane release from guinea-pig isolated perfused lung. Nature 328: 270–272, 1987PubMedCrossRefGoogle Scholar
  22. 22.
    Andree HSM, Reutelingsperger CPM, Hauptman R, Hemker HC, Hermens WT, Willems GM: Binding of vascular anticoagulant-alpha (VAC-α) to planar phospholipid bilayers. J Biol Chem 265: 4923–4928, 1990PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  1. 1.Department of Biochemistry Cardiovascular Research Instistute MaastrichtUniversity of LimburgMaastrichtThe Netherlands
  2. 2.Physiology and Biochemistry Cardiovascular Research Instistute MaastrichtUniversity of LimburgMaastrichtThe Netherlands

Personalised recommendations

Cite chapter

Buy options